Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1314-1319

  Huang, Hua ^a   Zhang, Xiao Fei ^b   Zhou, Hai Jun ^a   Xue, Yu Hua ^a   Dong, Qiong Zhu ^b   Ye, Qing Hai ^a   Qin, Lun Xiu ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; OSTEOPONTIN;

ADULT; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 77953201959     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01524.x     Document Type: Article

References (31)

1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-34.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
3. Tang ZY, Ye SL, Liu YK. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:187-96.
4. Yang Y, Nagano H, Ota H. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007, 141:196-202.
5. El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 2008, 13:4276-84.
6. Khodavirdi AC, Song Z, Yang S. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006, 66:883-8.
7. Coppola D, Szabo M, Boulware D. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-90.
8. Sedivy R, Peters K, Kloppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005, 446:41-5.
9. Gu T, Ohashi R, Cui R. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 2009, 66:176-83.
10. Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007, 26:2840-50.
11. Kim J, Ki SS, Lee SD. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006, 101:2051-9.
12. Zhang H, Ye QH, Ren N. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:709-17.
13. Ye QH, Qin LX, Forgues M. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-23.
14. Pan HW, Ou YH, Peng SY. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003, 98:119-27.
15. Ho PK, Hawkins CJ. Mammalian initiator apoptotic caspases. FEBS J 2005, 272:5436-53.
16. Cui JF, Liu YK, Zhang LJ. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006, 6:5953-61.
17. Wu X, Jia HL, Wang YF. HTPAP gene on chromosome 8p is a candidate metastasis suppressor for human hepatocellular carcinoma. Oncogene 2006, 25:1832-40.
18. Bu X, Jia F, Wang W, Guo X, Wu M, Wei L. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer 2007, 7:208.
19. Johansson O, Liang Y, Heilborn JD, Marcusson JA. Langerhans cells in prurigo nodularis investigated by HLA-DR and S-100 immunofluorescence double staining. J Dermatol Sci 1998, 17:24-32.
20. Sun HC, Zhang W, Qin LX. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007, 47:684-90.
21. Shah SA, Cleary SP, Wei AC. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007, 141:330-9.
22. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004, 10:S115-20.
23. Marrero JA, Fontana RJ, Barrat A. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-16.
24. Qian YB, Zhang JB, Wu WZ. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 2006, 107:1562-9.
25. Gao Q, Qiu SJ, Fan J. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-93.
26. Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
27. Zhu XD, Zhang JB, Zhuang PY. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008, 26:2707-16.
28. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-7.
29. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002, 52:19-24.
30. Sun J, Xu HM, Zhou HJ. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136:1-7.
31. Sun BS, Dong QZ, Ye QH. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008, 48:1834-42.